Article

A Combination of Imatinib Mesylate and Pegylate Interferon a2a in Chronic-phase CML

The goal of this study is to determine whether the addition of the drug pegylated interferon-a2a in combination with imatinib mesylate will allow the imatinib to target and kill the leukemic stem cells, hopefully putting the leukemia in remission without the need for continuous treatment.

Study Type: Interventional

Age/Sex Requirements: 18 years+ (None)

Sponsor: University of Michigan Cancer Center

Purpose: Imatinib mesylate is the standard first-line therapy for CML, controlling leukemia in a majority of patients by blocking the tyrosine kinase enzyme. However, imatinib mesylate does not kill the leukemic stem cells, and as a result is not curative. The goal of this study is to determine whether the addition of the drug pegylated interferon-a2a in combination with imatinib mesylate will allow the imatinib to target and kill the leukemic stem cells, hopefully putting the leukemia in remission without the need for continuous treatment.

Click here to access this third-party website.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
4 experts are featured in this series.
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.